PatientsVille.com Logo

BLOOD GLUCOSE INCREASED and Metronidazole

PatientsVille

BLOOD GLUCOSE INCREASED Symptoms and Causes

If you have diabetes or pre-diabetes you have an increased risk for heart disease. Diabetic heart disease can be coronary heart disease (CHD), heart failure, and diabetic cardiomyopathy.

Diabetes by itself puts you at risk for heart disease. Other risk factors include

  • Family history of heart disease
  • Carrying extra weight around the waist
  • Abnormal cholesterol levels
  • High blood pressure
  • Smoking

Some people who have diabetic heart disease have no signs or symptoms of heart disease. Others have some or all of the symptoms of heart disease.

Treatments include medications to treat heart damage or to lower your blood glucose (blood sugar), blood pressure, and cholesterol. If you are not already taking a low dose of aspirin every day, your doctor may suggest it. You also may need surgery or some other medical procedure. Lifestyle changes also help. These include a healthy diet, maintaining a healthy weight, being physically active, and quitting smoking.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for BLOOD GLUCOSE INCREASED

BLOOD GLUCOSE INCREASED treatment research studies

Metronidazole clinical trials, surveys and public health registries


Find Drug Side Effect reports



Metronidazole Side Effects

Dysarthria (124)
Dizziness (124)
Vomiting (119)
Nausea (108)
Encephalopathy (106)
Diarrhoea (102)
Paraesthesia (93)
Headache (88)
Confusional State (80)
Ataxia (80)
Toxic Encephalopathy (71)
Pruritus (67)
Gait Disturbance (62)
Neuropathy Peripheral (60)
Pain (60)
Pyrexia (58)
Cerebellar Syndrome (58)
Rash (56)
Urticaria (51)
Malaise (49)
Neurotoxicity (44)
Anaphylactic Reaction (44)
Abdominal Pain (43)
Dyspnoea (42)
Anxiety (41)
Dysgeusia (41)
International Normalised Ratio Increased (39)
Asthenia (38)
Hypoaesthesia (37)
Fatigue (37)
Convulsion (34)
Somnolence (34)
Nuclear Magnetic Resonance Imaging Brain Abnormal (32)
Pain In Extremity (31)
Coordination Abnormal (31)
Arthralgia (31)
Abdominal Pain Upper (30)
Balance Disorder (30)
Clostridium Difficile Colitis (30)
Depression (30)
Chest Pain (30)
Cerebellar Ataxia (29)
Insomnia (28)
Dysphagia (27)
Condition Aggravated (27)
Feeling Abnormal (27)
Psychotic Disorder (27)
Nystagmus (26)
Liver Function Test Abnormal (26)
Muscular Weakness (25)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

<b>Describe Your Metronidazole Experience Here:</b> after taking a total of 4 pills, 1 first day 2 second day and 1 in third day. I had symptoms begin on that second day. There was tingling in my lips with burning in my lips and tongue. T

Can I take Flagyl for a UTI?

Dentist gave me 400mg of metronidazole for toothache i feel sick and dizzy i keep going hot and cold and my skin goes red

Diagnosed with BV and started taking Flagyl orally twice per day for 7 days. In the 4th day of my treatment my period started. Had very heavy flow. No cramps but very heavy menstrual bleeding and passed large blood clots

Diahorrea, metallic taste in the mouth, burning vagina feeling sick bad stomach

Experienced palpitation

Hi just been discharged from A&amp;E. Meronidazeole 400mg. I had severe racing heart beats (resting pulse normally 53 became 90-100! and would go to 140 with no prompting). Blood pressure usually 120/60 became 135/90&gt;. Breathing was di

Hi,am 21 years old from phil. am engaging sex so many times for ten guys,time came that am discharging something unpleasant and yellow in color am shy to check a doctor so i just try to search some knowledge on net then am trying using metronidazole

I am a 18 yr old, i was pescribed metro for a infection.... 2 days into i was feeling very paranoid and frightened, last night i experienced two encounters of wide awake, shaking, grunting, crying and coldness. scareyyy :'(

I am deeply indebted to Danny Smith with his comments about metronidazole. I was also prescribed metronidazole for a tooth complaint and after experiencing dizziness and being very unwell with nausea, happened to find his remarks on the net. A

I've been taking Coversyl for almost two weeks now. My doctor prescribed it when the Natrilix I had been taking for a couple of months wasn't bringing my blood pressure down fast enough. The only side effects I've noticed since commencing the C

Does panadeine increase blood pressure?

I HAD 1 SHOT OF THIS AND WITHIN 12 HOURS I WENT FROM A VERY NORMAL BLOOD PRESSURE TO WAKING AT 5 A.M. NEXT DAY WITH 198/110 AND 104 PULSE RATE. IT HAS CONTINUED ALL WEEK AFTER AND I'M NOW ON A BLOOD PRESSURE DRUG TO TRY AND CONTROL IT. EVEN WITH DR

I have been put on Molipaxin 3 weeks ago, I have dry mouth, hair loss and my panic attacks were showing no signs of improvement. Dr increased it to 100mg and put me onto Lamictin. I am not bi polar nor epileptic. My disorder ist algora phoebia. I a

I have just come back from a funeral for my brother. He was just 62. He was on statin medicine but his cholestrol, blood pressure, weight and diet was very much in control. In fact just a day before his death the doctor told him that he was doing f

Side effects I have from Nadolol are confusion, dizziness, lightheaded, increased depression and anxiety, and mild nausea.

Since taking Karvezide (2years after Karvea was proved to unsuccessfull in reducing my high blood pressusre) I have experienced a lot of problems with nasal drip and a permanent muscas build up in the throat. Nothing seems to relieve the problem.

When I reported to my doctor that i was frequently having to urinate he had a blood test carried out with the result that my prostrate was OK he prescribed Permixon 160 mg twice per day and Tamsulosina STADA 0,4 mg once per day. I am now urinating

Have taken hydrea for a year because my spleen had increased in size. I have noticed increased loss of memory and some confusion for the past couple of months. I take 500 mg every other day and 1000 mg every other day.

fell dizziness and was admitted. Doc execute with dianostic including blood teat and heart check all. good. Doc make a decision by saying i'm getting Vertigo and treat with BETASERC. Below is the effect after 2 days take this medicine:- I was

BLOOD GLUCOSE INCREASED Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies
Conditions: Abnormal Vaginal Flora;   Clindamycin Vs Metronidazole;   High Risk Pregnancies for Preterm Labor
Interventions: Drug: Clindamycin;   Drug: Metronidazole
Outcome Measures: To compare the efficacy between oral Clindamycin Vs Metronidazole in the eradication of abnormal vaginal flora;   The prevalence of adverse effects;   The prevalence of late abortions and preterm deliveries;   Assessing the correlation between Nugent score , physical examination and Ph indicators
2 Recruiting Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Azithromycin + Metronidazole;   Drug: Metronidazole
Outcome Measures: Response rate at 8 weeks defined as a drop in PCDAI (Pediatric Crohn's Disease Activity Index ) of at least 12.5 points (or remission without steroids, intention to treat principle);   Normalization of CRP ( CRP ≤0.5 mg/dL).;   Fecal calprotectin at 8 weeks .
3 Not yet recruiting Study to Determine the Equivalence of Three Products Containing Metronidazole Benzoate.
Condition: Bacterial Infections
Interventions: Drug: Metronidazole benzoate;   Drug: Flagyl 125 mg/5 ml oral suspension;   Drug: Flagyl 400 mg Tablets
Outcome Measures: Plasma concentration time profiles under the curve (AUC);   Maximum concentration (Cmax);   Time to maximum concentration (Tmax);   Elimination rate constant (Kel);   Terminal half life (t1/2);   Number of participants with Adverse Events
4 Recruiting BASIC (Boric Acid, Alternate Solution for Intravaginal Colonization) Study
Condition: Bacterial Vaginosis
Interventions: Drug: Gelatin;   Drug: Boric acid;   Drug: Metronidazole
Outcome Measures: Effectiveness of treatment of intravaginal boric acid and Metronidazole at 1 week and 30 days post-treatment will be measured as absence of symptoms or negative vaginal swab (Nugent score less than 7) if symptoms are present for BV.;   If during the 10 days of treatment of intravaginal boric acid and Metronidazole the patient discontinues the treatment because of side effects or complained of intolerable side effects this will be considered a treatment failure for safety.
5 Unknown  Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy
Condition: Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Interventions: Drug: 10RAC+acetylcystein;   Drug: 10RAC+Metronidazole
Outcome Measures: Re-eradication rate;   Influence of Participant's CYP2C19 genotype on re-eradication rate
6 Unknown  Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses
Condition: Abscess, Intra-Abdominal
Intervention: Drug: Moxifloxacin/Metronidazole or Piperacillin/Tazobactam
Outcome Measures: Clinical success / failure rate at the Test-of-Cure visit;   Clinical + Bacteriological response at End-of-Treatment-visit;   Time to discharge from hospital;   Course of disease on the basis of clinical and laboratory parameters;   safety and tolerability of the study medication;   cost effectiveness of treatment regimes
7 Recruiting Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
Condition: Complicated Intra-Abdominal Infection
Interventions: Drug: CAZ-AVI;   Drug: Metronidazole;   Drug: Meropenem
Outcome Measures: Clinical Cure as Measured by proportion of patients meeting cure criteria in the microbiological modified Intent-To-Treat analysis set.;   The proportion of patients with clinical cure in the microbiologically evaluable and extended microbiologically evaluable analysis set;   The proportion of patients with clinical cure in the microbiological modified intent-to-treat, microbiologically evaluable, and extended microbiologically evaluable analysis sets;   The proportion of patients with clinical cure in the clinically evaluable analysis set.;   The proportion of patients with a favorable per-patient microbiological response in the microbiological modified intent to treat, microbiologically evaluable, and extended microbiologically evaluable analysis sets;   The proportion of favorable per-pathogen microbiological response in the microbiological modified intent to treat, microbiologically evaluable, and extended microbiologically evaluable analysis sets;   The favorable per-pathogen microbiologic response by minimum inhibitory concentration (MIC) categories in the microbiological modified intent to treat, microbiologically evaluable, and extended microbiologically evaluable analysis sets;   Favorable per-patient clinical response & microbiological response for patients infected with ceftazidime-resistant pathogens in microbiological modified intent to treat, microbiologically evaluable & extended microbiologically evaluable analysis sets;   Proportion of patients with favorable per-pathogen microbiological response for patients infected with ceftazidime-resistant pathogens in microbiological modified ITT, microbiologically evaluable and extended microbiologically evaluable analysis sets;   The time to first defervescence in the clinically evaluable, microbiologically evaluable, and extended microbiologically evaluable analysis sets for patients who have fever at study entry;   The safety and tolerability by incidence and severity of adverse events and serious adverse events, vital signs, clinical laboratory tests, ECGs and physical exams.;   Pharmacokinetics: maximum concentration (Cmax), minimum concentration, area under the plasma concentration time curve at steady state, and terminal half-life
8 Recruiting Role of N-Acetylcysteine in Treatment of Bacterial Vaginosis
Condition: Bacterial Vaginosis
Interventions: Drug: N-Acetyl cysteine;   Drug: Metronidazole + N-Acetyl cysteine;   Drug: Metronidazole
Outcome Measures: recovery of BV;   prevention of recurrence
9 Recruiting Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections
Condition: Complicated Intra-abdominal Infection
Interventions: Drug: Ceftazidime-avibactam;   Drug: Metronidazole;   Drug: Meropenem
Outcome Measures: The proportion of patients with clinical cure in the clinically evaluable analysis set;   The proportion of patients with clinical cure in the microbiologically evaluable, extended microbiologically evaluable and microbiological modified intent-to-treat analysis sets;   The proportion of patients with a favorable per-patient microbiological response in the microbiological modified intent to treat, microbiologically evaluable and extended microbiologically evaluable analysis sets;   The proportion of favorable per-pathogen microbiological response in the microbiological modified intent to treat, microbiologically evaluable and extended microbiologically evaluable analysis sets;   The favorable per-pathogen microbiologic response by minimum inhibitory concentration categories in the microbiological modified intent to treat, microbiologically evaluable and extended microbiologically evaluable analysis sets;   Favorable clinical response and favorable per-patient microbiological response for patients infected with ceftazidime-resistant pathogens in the microbiological modified intent to treat and (extended) microbiologically evaluable analysis sets;   The proportion of patients with a favorable per-pathogen microbiological response for patients infected with ceftazidime-resistant pathogens in the microbiological modified intent to treat and (extended) microbiologically evaluable analysis sets;   The time to first defervescence in the clinically evaluable, microbiologically evaluable and extended microbiologically evaluable analysis sets for patients who have fever at study entry;   Safety and tolerability by incidence and severity of adverse events and serious adverse events, exposure, mortality, reasons for discontinuations of study therapy, vital signs, laboratory tests, electrocardiogram parameters and physical exams
10 Unknown  Effects of the Variation in the Time of Systemic Administration of Metronidazole and Amoxicillin Associated to the Non-surgical Therapy of Chronic Periodontitis.
Conditions: Chronic Periodontitis;   Clinical and Microbiological Effects
Intervention: Drug: Administration of Metronidazole plus Amoxicillin
Outcome Measures: - Mean change in clinical attachment level (CAL);   - Mean change in probing pocket depths (PD)
11 Recruiting Impact of Oral Antibiotic Treatment on C. Difficile
Conditions: C. Difficile;   Diarrhea;   Enterocolitis
Interventions: Drug: Fidaxomicin;   Drug: Metronidazole;   Drug: Vancomycin
Outcome Measures: Change in variation of the profile of C. difficile isolated from specific body sites of a patient with microbiology-proven CDAD;   Change in variation in the profile of C. difficile isolated from targeted surfaces in a hospital;   Extent and quantity of C. difficile shedding, colonization and environmental contamination in patients who received oral fidaxomicin vs. oral Metronidazole or vancomycin;   Duration of diarrhea that were positive for CDAD
12 Recruiting The Use of Erythritol Powder and Metronidazole Gel for the Non-surgical Treatment of Periodontitis
Condition: Periodontal Pocket
Interventions: Drug: Metronidazole gel;   Procedure: ultrasonics;   Procedure: erythritol;   Drug: placebo
Outcome Measures: Probing pocket Depth change;   Bleeding on Probing change;   Clinical Attachment level change
13 Unknown  Inflammation and Treatment of Bacterial Vaginosis Near Term
Condition: Bacterial Vaginosis
Interventions: Drug: Metronidazole;   Drug: Placebo
Outcome Measure: Levels of Interleukins 1 and 6 as well as Tumor Necrosis Factor Alpha
14 Recruiting Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy
Condition: Helicobacter Pylori Infection
Interventions: Drug: pantoprazole, amoxicillin, clarithromycin, Metronidazole;   Drug: pantoprazole, amoxicillin, clarithromycin, metronidzole
Outcome Measure: Comparison of the eradications rates of sequential therapy versus concomitant therapy of treatment of Helicobacter pylori infection in Korea.
15 Unknown  The Impact of Obesity on Nonsurgical Periodontal Therapy
Conditions: Periodontitis;   Periodontal Diseases;   Obesity
Interventions: Drug: Metronidazole;   Drug: Placebo;   Procedure: Scaling and root planning
Outcome Measures: Probing depth;   Attachment level
16 Recruiting Antibiotic Safety (SCAMP)
Condition: Complicated Intra Abdominal Infections
Interventions: Drug: ampicillin and Metronidazole and gentamicin;   Drug: ampicillin and gentamicin and clindamycin;   Drug: gentamicin and Piperacillin- tazobactam;   Drug: standard of care antibiotics and Metronidazole
Outcome Measures: Death;   Number of participants with therapeutic success at Day 30 and Day 90
17 Recruiting Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI)
Condition: Postoperative Ileus
Interventions: Drug: DAM;   Drug: Normal Saline
Outcome Measures: Time to achieve recovery of both upper and lower GI function as measured by a composite endpoint of time to the first bowel movement and time to tolerate first solid food. This endpoint is referred to as GI2.;   Time to ready for discharge;   Time to the first flatus;   Comparison between the 2 groups of analgesics (morphine) dose;   peritoneal exudate volume of 72 hours after operation;   C reactive protein changes from baseline
18 Recruiting Concomitant Therapy of H. Pylori
Condition: Gastritis, Gastric Ulcer, and Duodenal Ulcer
Intervention: Drug: amoxicillin, clarithromycin, Metronidazole, rabeprazole
Outcome Measure: Evaluation of the efficacy of concomitant therapy for eradication of Helicobacter pylori
19 Recruiting Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population
Conditions: Vaginosis, Bacterial;   Infertility;   Miscarriage
Interventions: Drug: Metronidazole;   Drug: Placebo
Outcome Measures: Biochemical Pregnancy Rate (Positive Pregnancy Test);   Pregnancy Rate (Pregnancy Visible on Ultrasound);   Miscarriage Rate (Loss of a Clinically Recognized Pregnancy);   Infectious Morbidity (i.e. Chorioamnionitis, Neonatal Sepsis)
20 Recruiting Multi-center Clinical Study of Early Antibios of Severe Acute Pancreatitis
Condition: Pancreatitis,Acute Necrotizing
Interventions: Drug: cefoperazone + Metronidazole;   Procedure: oral care by chlorhexidine gluconate;   Procedure: enteral nutrition;   Drug: Somatostatin;   Drug: Meropenem
Outcome Measures: pancreatic or peripancreatic infection;   cost of management of SAP;   Microbiology resistance